Das Herzklappenreparaturgerät von Abbott erhält die US-amerikanische FDA-Zulassung

> Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards Lifesciences received the regulator’s nod for its device.

> The Abbott device, TriClip, aims to treat tricuspid regurgitation (TR), which occurs when the valve separating the right lower chamber of the heart from the right upper does not close properly, causing blood to flow backwards.

…

> It is estimated about 1.6 million Americans are affected by the condition, according to government data.

> Unlike the Edwards rival, Abbott’s device repairs the tricuspid valve by clipping a portion of its flaps to reduce the backflow of blood.

> Other options to treat the disease include diuretic drugs, which make patients urinate frequently to prevent a buildup of fluid in the body.

Abbot’s product page for TriClip: https://www.cardiovascular.abbott/int/en/hcp/products/structural-heart/triclip.html